Table 1.
Demographic and clinical characteristics of the study population
| Parameters | Value | Range |
|---|---|---|
| Demographics | n = 145 | |
| Gender | ||
| Female, n (%) | 72 (49.7%) | |
| Male, n (%) | 73 (50.3%) | |
| Age (years) | 70.4 ± 7.7 | 49–90 |
| Age | ||
| < 65 years, n (%) | 30 (20.7%) | |
| ≥ 65 years, n (%) | 115 (79.3%) | |
| Age > 70 years, n (%) | 78 (53.8%) | |
| PD medical history | ||
| Age at PD diagnosis (years) | 55.7 ± 9.27 | |
| PD duration (years) | 14.61 ± 6.58 | 1.3–46.7 |
| PD duration ≤ 13 years | 72 (49.7%) | |
| PD duration > 13 years | 73 (50.3%) | |
| Time since onset of motor fluctuations (years) (n = 143) (mean ± SD) | 5.9 ± 4.0 | 1–21 |
| Previous use of invasive treatments (before LCIG infusion) | N(%) | Daily dose, mean ± SD |
| Previous deep brain stimulation | 3 (2.1%) | NA |
| Apomorphine SC (pump) (mg) | 14 (9.7%) | 86.29 (46.38) |
| Apomorphine stylo (mg) | 7 (4.8%) | 6.5 (10.6) |